Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real-world clinical setting

Hematol Oncol. 2024 Sep;42(5):e3306. doi: 10.1002/hon.3306.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Antibodies, Monoclonal* / administration & dosage
  • Antibodies, Monoclonal* / adverse effects
  • Antibodies, Monoclonal* / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols* / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Dexamethasone* / administration & dosage
  • Dexamethasone* / adverse effects
  • Dexamethasone* / therapeutic use
  • Female
  • Gene Amplification
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma* / drug therapy
  • Multiple Myeloma* / genetics
  • Oligopeptides* / administration & dosage
  • Oligopeptides* / adverse effects
  • Oligopeptides* / therapeutic use
  • Treatment Outcome

Substances

  • daratumumab
  • carfilzomib
  • Dexamethasone
  • Oligopeptides
  • Antibodies, Monoclonal